Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | HTR2B | P41595 | 6/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.42 |
| ▸ | TSPO | P30536 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401993 | 1.00 | ADORA1 (0.42) | ADORA1ADORA3ADORA2AHTR2CHTR2B | |
| SCHEMBL588937 | 0.83 | ADORA3 (0.53) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL240045 | 0.83 | ADORA3 (0.46) | ADORA1ADORA3ADORA2AHTR2CHTR2B | |
| SCHEMBL4220375 | 0.83 | ADORA3 (0.46) | ADORA1ADORA3ADORA2AHTR2CHTR2B | |
| SCHEMBL14018046 | 0.81 | HTR2C (0.40) | ADORA1ADORA3ADORA2AHTR2CHTR2B | |
| SCHEMBL1908715 | 0.80 | HTR2C (0.41) | ADORA1ADORA3ADORA2AHTR2CHTR2B | |
| SCHEMBL241618 | 0.80 | LMNA (0.46) | ADORA1ADORA3ADORA2AHTR2CHTR2B | |
| SCHEMBL242801 | 0.78 | ADORA1 (0.37) | ADORA1ADORA3ADORA2AHTR2CHTR2B | |
| SCHEMBL1412357 | 0.75 | ADORA3 (0.39) | ADORA1ADORA3ADORA2AHTR2CHTR2B | |
| SCHEMBL242153 | 0.74 | ADORA2A (0.49) | ADORA1ADORA3ADORA2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2292619-A1 | Purine derivatives for use as adenonsin A-2A receptor agonists | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA1 1271/4885ADORA3 795/4885ADORA2A 2741/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA1 1271/4885ADORA3 795/4885ADORA2A 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.